PIRPHYTO

Piramal Phytocare Limited has informed the Exchange that the Annual General Meeting (AGM) of the Shareholders of the Company was held on July 7, 2014. All resolutions contained in the Notice dated 29th April 2014 convening the AGM were duly passed. The voting was undertaken at the AGM by way of Poll.

Piramal Phytocare Limited has submitted to the exchange the standalone financial results for the period ended 30-Jun-2014.

The Sri Krishna Trust has informed the Exchange vide letter dated July 09, 2014 regarding disclosure under Regulation 10(5) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (SEBI SAST)- ELAPSED.

The Sri Krishna Trust has informed the Exchange vide letter dated July 04, 2014 regarding disclosure under Regulation 10(5) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (SEBI SAST)- Elapsed.

The Sri Krishna Trust has submitted to the Exchange vide letter dated June 25, 2014 a copy of disclosure under Regulation 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

The Sri Krishna Trust has submitted to the Exchange vide its letter dated June 19, 2014 a copy of disclosure under Regulation 10(5) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Piramal Phytocare Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from July 09, 2014 to July 17, 2014 (both days inclusive) for the purpose of Annual General Meeting of the Company to be held on July 17, 2014.

Piramal Phytocare Limited has submitted to the exchange the standalone financial results for the period ended 31-Mar-2014.

Piramal Phytocare Limited has submitted to the exchange the standalone financial results for the period ended 31-dec-2013.

Piramal Phytocare Limited has informed the Exchange that Mr. Neelesh Bhise, a member of The Institute of Company Secretaries of India has been appointed as the Company Secretary of the Company with effect from December 04, 2013.

Piramal Phytocare Limited has informed the Exchange that Mr. Ankit Sheth resigned as the Company Secretary of the Company effective November 07, 2013.

Piramal Phytocare Limited has informed the Exchange that the Board of Directors of the Company at its Meeting held on October 24, 2013 took on record resignation of Dr. Somesh Sharma who has step down as Director of the Company. The Board of Directors have placed on record their appreciation and gratitude for the invaluable contributions made by Dr. Somesh Sharma during his tenure as member of the Board.

Piramal Phytocare Limited has submitted to the exchange the standalone financial results for the period ended 30-sep-2013.

Members of the Exchange are hereby informed that the name of Piramal Life Sciences Limited shall be changed to Piramal Phytocare Limited and the trading symbol of the Company be changed from PIRLIFE to PIRPHYTO w.e.f. October 23, 2013.

Piramal Life Sciences Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended June 30,2013.

Piramal Life Sciences Limited has informed the Exchange that the Board of Directors of the Company have approved the proposal to change the name of the Company from Piramal Life Sciences Limited to Piramal Phytocare Limited or such other name as may be approved by the Registrar of Companies / other statutory authorities. Until recently, the word "Life Sciences" in the name of the Company appropriately reflected the research and development activity carried out by the Company. Consequent to the demerger of the NCE Research Unit of the Company to Piramal Enterprises Limited, the current business

Piramal Life Sciences Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2013.

Piramal Life Sciences Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended December 31,2012.

PHL Holdings Private Limited has submitted to the Exchange vide letter dated December 28, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 and Regulation 13(3) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

The Sri Krishna Trust has submitted to the Exchange vide letter dated January 02, 2013 a Copy of Disclosures under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Piramal Life Sciences Limited has submitted to the Exchange vide letter dated December 31, 2012 a copy of Disclosure under Regulation 13(1), 13(2), 13(2A), 13(3), 13 (4), 13(4A) & 13 (6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Propiedades Realties Pvt ltd has submitted to the Exchange vide its letter dated December 31, 2012 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Propiedades Realties Pvt ltd has submitted to the Exchange vide its letter dated December 31, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Piramal Life Sciences Limited has submitted to the Exchange vide letter dated December 31, 2012 a copy of Disclosure under Regulation 13(6) r/w 13(1), 13(2A), 13(3) and 13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

The Sri Krishna Trust has submitted to the Exchange vide letter dated December 28, 2012 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure pursuant to Regulation 13(1), 13(2), 13(3), 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

The Sri Krishna Trust has submitted to the Exchange vide letter dated December 12, 2012 a Copy of Disclosures under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The Sri Krishna Trust has submitted to the Exchange vide letter dated November 20, 2012 a copy of Disclosure under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Piramal Life Sciences Limited has submitted to the Exchange vide letter dated November 07, 2012 a copy of Revised Disclosure under Regulation 13(3) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Piramal Life Sciences Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended September 30, 2012.

PHL Holdings Private Limited has submitted to the Exchange vide letter dated October 30, 2012 a copy of Disclosure under Regulation 29(1) and 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Share and Takeovers) Regulations, 2011 ('SEBI Takeover Regulation') along with a copy of Disclosure under Regulation 13(4A) and 13(3) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 ('SEBI Insider Trading Regulations').

Paramount Pharma Private Limited has submitted to the Exchange vide its letter dated October 30, 2012 a copy of Disclosure under Regulation 13 (3), 13(4), 13(4A) and 13(6) of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992 (SEBI Insider Trading Regulation).

Piramal Life Sciences Limited has submitted to the Exchange vide letter dated November 01, 2012 a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Piramal Life Sciences Limited has submitted to the Exchange vide letter dated November 01, 2012 a copy of Disclosure under Regulation 13(3) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Piramal Life Sciences Limited has submitted to the Exchange vide letter dated November 01, 2012 a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Piramal Life Sciences Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2012.

Piramal Life Sciences Limited has informed the Exchange regarding the Outcome of Annual General Meeting of the shareholders of the Company held on August 03, 2012.

Piramal Life Sciences Limited has informed the Exchange that Ms.Vandana Chablani has ceased to be the Company Secretary of the Company with effect from May 19, 2012 and Mr. Ankit Sheth has been appointed as Company Secretary of the Company in her place.

Piramal Life Sciences Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2012.

Piramal Life Sciences Limited has informed the Exchange that the Company will declare / publish Audited Financial Results for the financial year ended March 31, 2012 within a period of sixty (60) from the end of the financial year i.e. on or before May 30, 2012. Accordingly, the Company will not be declaring / publishing unaudited results for the last quarter ended March 31, 2012.

Piramal Life Sciences Limited has submitted to the Exchange the Standalone Financial Results along with Limited Review Report for the period ended December 31,2011.

Price movement : Significant price movement has been observed in Piramal Life Sciences Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Piramal Life Sciences Limited has vide its letter inter-alia stated, "We are not aware of any information/announcement (including impending announcement) which in our opinion may have a bearing on the price/volume behaviour in the scrip."

Piramal Life Sciences Limited has informed the Exchange that the Order of the Court sanctioning the Scheme of Arrangement between Piramal Life Sciences Limited and Piramal Healthcare Limited has been filed with the Registrar of Companies on December 14, 2011 and accordingly, the Scheme has become effective. Further, December 26, 2011 has been fixed as the Record Date for determining the entitlement of the Shareholders of Piramal Life Science Limited ('the Company'), to receive the equity shares of Piramal Healthcare Limited ('PHL') in the ratio 1:4 (i.e. one equity share of Rs.2 of PHL for eve

Piramal Life Sciences Limited has informed the Exchange that the Hon'ble Bombay High Court on November 25, 2011 has sanctioned the Scheme of Arrangement for Demerger of the NCE Research Unit of Piramal Life Sciences Limited into Piramal Healthcare Limited. Shareholders of Piramal Life Sciences Limited ('PLSL') to receive the equity shares of Piramal Healthcare Limited ('PHL') in the ratio of 1:4 (i.e. one share of Rs. 2 each of PHL for every 4 shares of Rs. 10/- each held in PLSL) under the aforesaid scheme.

Piramal Life Sciences Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2011.

Piramal Life Sciences Limited had informed the Exchange that a meeting of the Board of Directors of the Company will be held on October 13, 2011 to consider and take on record the Un-audited Financial Results of the Company for the second quarter and half year ended September 30, 2011. The Company has now informed the Exchange that the in view of paucity of time, it was decided that the results for the quarter ended September 30, 2011 be considered at a subsequent meeting for which necessary advance intimation would be given by the Company.

Piramal Life Sciences Limited has informed the Exchange that at the Annual General Meeting of the members of the Company held on August 09, 2011 have approved the following: (1) Prof. Goverdhan Mehta has been re-appointed as a Director of the Company. (2) Sir Ravinder Maini has been re-appointed as a Director of the Company. (3) The Audited Accounts for the year ended March 31, 2011 were adopted. (4) M/s. Price Waterhouse & Co., Chartered Accountants, Mumbai have been re-appointed as Auditors of the Company.

Piramal Life Sciences Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2011.

Piramal Life Sciences Limited has informed the Exchange that by an Order made on July 08, 2011, in Piramal Life Sciences Limited ("the Applicant Company") Summons for Directions, the Hon'ble High Court of Judicature at Bombay has directed that a meeting of the Equity Shareholders of Piramal Life Sciences Limited, the Applicant Company, be convened and held on August 09, 2011 for the purpose of considering and, if thought fit, approving with or without modification(s), the proposed arrangement embodied in the Scheme of Arrangement between Piramal Life Sciences Limited and Piramal Healthcare Lim

Piramal Life Sciences Limited has informed the Exchange that at its meeting held on May 6, 2011, the Board considered and approved the Scheme of Arrangement between Piramal Life Sciences Limited (`PLSL') and Piramal Healthcare Limited ('PHL') (`Demerger Scheme'). Under the proposed Demerger Scheme, the New Chemical Entity (NCE) Research Unit would be transferred from PLSL to PHL with effect from April 1, 2011, which is the Appointed Date under the Demerger Scheme. The following exchange ratio has been approved: "1 [one] fully paid up equity shares of Rs. 2/- of PHL shall be issued and allotte

Piramal Life Sciences Limited has informed the Exchange regarding a press release dated May 06, 2011, titled " Piramal Life Sciences Limited and Piramal Healthcare Limited- Demerger of the NCE Research Unit of Piramal Life Sciences Limited into Piramal Healthcare Limited."